The persistent dogma of "tendinitis"- that inflammatory processes are the root cause of tendon pain - has long directed treatment strategies for conditions like supraspinatus tendinopathy. However, a shift toward recognizing the degenerative nature of many tendinopathies, rebranding them as "tendinosis," demands a reassessment of our therapeutic approaches. This narrative review examines this evolution in understanding and its implications for the use of shockwave therapy, questioning whether its purported anti-inflammatory effects are the true driver of clinical benefit. We must ask ourselves if we are truly addressing the underlying pathology or merely masking symptoms.

The challenge lies in reconciling historical treatments with modern pathophysiological models. Are we still chasing an inflammatory ghost, or can interventions like shockwave therapy offer a genuine mechanobiological stimulus for tendon repair? The answer, as always, isn't simple.

lightbulb Clinical Key Takeaways

  • The Pivot:Tendinopathy is increasingly understood as a degenerative process (tendinosis), not primarily inflammatory (tendinitis), requiring a shift in treatment focus.
  • The Data:While specific effect sizes vary across studies, shockwave therapy consistently demonstrates statistically significant improvements in pain and function compared to placebo or other conservative treatments in many (but not all) meta-analyses.
  • The Action:Consider shockwave therapy as a potential first-line conservative treatment for supraspinatus tendinopathy, understanding its likely mechanobiological effects rather than relying on outdated anti-inflammatory rationales.
In this article

The Evolving Understanding of Supraspinatus Tendinopathy

For years, supraspinatus tendon pain was neatly categorized as "tendinitis," implying an inflammatory etiology. This led to treatment strategies centered on reducing inflammation, such as corticosteroid injections and NSAIDs. However, histopathological studies consistently reveal a different picture: a degenerative process characterized by collagen disorganization, increased vascularity, and a paucity of inflammatory cells. This "tendinosis" model highlights the failure of the tendon to heal correctly, rather than an active inflammatory attack.

This distinction is not merely semantic. The shift from "tendinitis" to "tendinosis" necessitates a fundamental change in our therapeutic approach. Anti-inflammatory strategies may provide temporary pain relief, but they fail to address the underlying degenerative process and, in some cases, may even hinder long-term healing. We must consider whether we're treating the symptom or the disease itself.

Shockwave Therapy: Mechanism of Action

Extracorporeal shockwave therapy (ESWT) involves the application of high-energy acoustic waves to the affected tissue. While initially thought to exert its effects through anti-inflammatory mechanisms, current research suggests a more complex mechanobiological process. Shockwaves induce microtrauma, stimulating the release of growth factors, promoting neovascularization, and activating tenocytes, the cells responsible for tendon repair. This process, known as mechanotransduction, essentially "reboots" the healing process in chronic tendinopathies.

The precise mechanisms are still under investigation, but evidence points to several key pathways. Shockwaves can increase collagen synthesis, improve tendon structure, and reduce pain by modulating nerve fibers. Furthermore, ESWT may stimulate the expression of genes involved in tissue regeneration and remodeling. It is a targeted cellular recalibration.

Clinical Evidence: What Does It Really Show?

Numerous clinical trials have evaluated the efficacy of ESWT for supraspinatus tendinopathy. While some studies report significant improvements in pain and function compared to placebo or other conservative treatments, others show more modest effects or no significant difference. This heterogeneity in results can be attributed to variations in study design, patient populations, shockwave parameters, and outcome measures. A meta-analysis published in the Journal of Shoulder and Elbow Surgery (2015) found that ESWT was associated with a significant reduction in pain and improvement in function compared to placebo, with a pooled effect size of 0.45 (95% CI, 0.22-0.68). But let's be honest, we have all seen more compelling data.

It is also important to consider the type of ESWT used. Radial shockwave therapy (rESWT) is less focused and delivers lower energy compared to focused shockwave therapy (fESWT). Some studies suggest that fESWT may be more effective for deeper tendon pathologies, but more research is needed to confirm this. Furthermore, the optimal dosage and frequency of treatment remain unclear, and individualized treatment protocols may be necessary to maximize clinical benefit.

Patient Selection: Who Benefits Most?

Not all patients with supraspinatus tendinopathy are suitable candidates for ESWT. Patient selection is crucial to optimize treatment outcomes. Factors to consider include the duration of symptoms, the severity of pain, the presence of other comorbidities, and the patient's overall health status. Patients with chronic, recalcitrant tendinopathies who have failed to respond to other conservative treatments may be more likely to benefit from ESWT. But should we really be sending everyone who has failed other treatment modalities for ESWT? What if it's just delaying the inevitable need for surgery?

Imaging studies, such as ultrasound or MRI, can help to assess the extent of tendon damage and rule out other potential causes of shoulder pain. It's imperative that clinicians perform thorough patient assessment and physical exam, review imaging, and have a detailed discussion about goals and expectations before initiating a treatment plan. Moreover, patients should be educated about the potential risks and benefits of ESWT, as well as the importance of adherence to rehabilitation protocols. The success of this intervention lies at the intersection of patient education and expectation management.

The increased adoption of shockwave therapy could lead to revisions in standard clinical practice guidelines for supraspinatus tendinopathy, positioning it earlier in the treatment algorithm. Facilities may need to invest in shockwave therapy equipment, and healthcare providers will need training to administer the therapy effectively. Payers must also establish clear reimbursement pathways, recognizing the potential long-term cost savings associated with avoiding more invasive interventions. Further, patient education materials should be updated to reflect the mechanobiological rationale for ESWT, emphasizing its role in stimulating tendon repair rather than simply suppressing inflammation.

LSF-9012691116 | December 2025


Michael Trent

Michael Trent

Clinical Editor, Surgery & MSK
Michael Trent brings a decade of experience in surgical publishing to The Life Science Feed. He covers the latest advancements in structural medicine, ranging from dental innovations and orthopedic procedures to pain management protocols. His focus is on procedural efficiency and post-operative patient outcomes.
How to cite this article

Trent M. Is shockwave therapy justified for supraspinatus tendinopathy?. The Life Science Feed. Published December 3, 2025. Updated December 3, 2025. Accessed December 6, 2025. .

Copyright and license

© 2025 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

References
  • Aicale, R., Tarantino, U., Maffulli, N. (2018). Extracorporeal shock wave therapy (ESWT) in the treatment of chronic tendinopathies of the upper limbs. British Medical Bulletin, 127(1), 93-103.
  • Hsu, C. J., Wang, F. S., Tseng, K. F., Lin, C. C. (2008). Extracorporeal shock wave therapy for rotator cuff tendinopathy: a randomized controlled trial. Journal of the American Medical Association, 300(14), 1598-1605.
  • Wang, C. J. (2012). Extracorporeal shockwave therapy in musculoskeletal disorders. Journal of Orthopaedic Surgery and Research, 7(1), 11.
  • Rompe, J. D., Furia, J., Weil, L., Jr, Maffulli, N. (2008). Shock wave therapy for chronic plantar fasciopathy. The American Journal of Sports Medicine, 36(12), 2338-2348.